These authors contributed equally to this work.
Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis†
Article first published online: 21 DEC 2011
Copyright © 2011 American Association for the Study of Liver Diseases
Volume 18, Issue 1, pages 62–69, January 2012
How to Cite
Liang, W., Wang, D., Ling, X., Allen Kao, A., Kong, Y., Shang, Y., Guo, Z. and He, X. (2012), Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis. Liver Transpl, 18: 62–69. doi: 10.1002/lt.22441
This study was supported by the National Science and Technology Pillar Program during the 11th 5-year planning period (Key Projects 2008BAI60B02 and 2008BAI60B06) and by the Key Clinical Project from the Ministry of Health (2010159) and Science and Technology Planning Project of Guangdong Province (Key Clinical Project 2008B030301308).
- Issue published online: 21 DEC 2011
- Article first published online: 21 DEC 2011
- Accepted manuscript online: 30 SEP 2011 08:17AM EST
- Manuscript Accepted: 10 SEP 2011
- Manuscript Received: 28 MAY 2011
- National Science and Technology Pillar Program. Grant Numbers: 2008BAI60B02, 2008BAI60B06
- Key Clinical Project from the Ministry of Health. Grant Number: 2010159
- Science and Technology Planning Project of Guangdong Province. Grant Number: 2008B030301308
Sirolimus (SRL) is a novel immunosuppressant with antitumor properties. We performed a meta-analysis to determine whether SRL can improve patient survival and decrease the risks of tumor recurrence in patients with a pretransplant diagnosis of hepatocellular carcinoma (HCC). We searched databases for controlled clinical trials assessing the survival and oncological benefits of SRL for liver transplant recipients with pretransplant HCC. Five studies with a total of 2950 participants were included in this study. In comparison with SRL-free regimens, SRL-based regimens improved overall survival at 1 [odds ratio (OR) = 4.53, 95% confidence interval (95% CI) = 2.31-8.89], 3 (OR = 1.97, 95% CI = 1.29-3.00), and 5 years (OR = 2.47, 95% CI = 1.72-3.55). The pooled results showed that in comparison with SRL-free regimens, SRL-based regimens decreased tumor recurrence (OR = 0.42, 95% CI = 0.21-0.83). No significant differences in the frequencies of episodes of major posttransplant complications were observed between the groups. In conclusion, SRL is generally safe and prolongs patient survival in liver transplant recipients with pretransplant HCC. Liver Transpl 18:62–69, 2012. © 2011 AASLD.